Telix ASX TLX Breaking News & Current Commentary, page-2830

1 + 1 = 2 Telix's USA commercialized Products are clearly influencing Cardinal Health revenue earnings growth according to this news.

In reverse this clearly signals that Telix's products are being sold at a rate that it affecting positively both Telix & Cardinal !

NB: There are no negative facts in these news release !!


Melbourne (Australia), Indianapolis, IN (U.S.A.) | 8 April 2025
Mike Pintek, President of Cardinal Health Nuclear & Precision Health Solutions, added, “We are pleased to continue to build on our relationship with Telix, which now includes the distribution of Illuccix®, Zircaix®[3] and Gozellix®. The combination of our extensive commercial distribution structure and the innovative ARTMS production technology enables us to broaden patient reach and scheduling flexibility for gallium-based PSMA imaging


Cardinal Health (NYSE:CAH) Launches Innovative Single-Patient Monitoring System to Enhance Patient Care

Simply Wall St

Thu, June 5, 2025 at 3:21 AM GMT+10 2 min read

In This Article:

CAH

-0.91%

Cardinal Health recently launched the Kendall DL™ Multi System, a notable advancement in patient monitoring technology aimed at improving clinical efficiency and patient safety. Accompanied by a dividend increase to $0.51 per share, the company's stock experienced a 22% rise over the last quarter. Earnings growth, with Q3 sales closely matching the previous year but net income nearly doubling, also supported this upward trajectory. The company’s stock buyback efforts and new distribution partnership with Telix Pharmaceuticals added further momentum, aligning with a generally rising market that saw a 13% gain over the past 12 months.

The dividend increase and stock buyback, paired with the strong Q3 earnings, underscore Cardinal Health's commitment to shareholder returns, while the partnership with Telix Pharmaceuticals may drive further opportunities in specialty segments.